• ANURAG VERMA
• Ms. Kritika Badola
• Dr. Praveen Kumar

Liposomal drug delivery systems have revolutionized chemotherapy by significantly improving the bioavailability and therapeutic efficacy of anticancer drugs while simultaneously reducing systemic toxicity. These nanoscale lipid-based vesicles encapsulate drugs, enabling targeted delivery and controlled release, which helps minimize the harmful side effects associated with conventional chemotherapy. Among anticancer agents, Doxorubicin Hydrochloride is widely used but limited by its cardiotoxicity and off-target effects. Liposomal encapsulation of Doxorubicin enhances its pharmacokinetics and tumor-specific accumulation, improving the safety profile and clinical outcomes. This review focuses on various formulation strategies employed for liposomal Doxorubicin, such as thin-film hydration, reverse-phase evaporation, and active drug loading techniques. It discusses the impact of lipid composition, particle size, surface modification (e.g., PEGylation), and encapsulation efficiency on the overall stability and functionality of the liposomes. In addition, the review highlights key characterization techniques including dynamic light scattering (DLS) for size distribution, zeta potential analysis for surface charge, and high- performance liquid chromatography (HPLC) for drug quantification. Evaluation of liposomal Doxorubicin involves comprehensive in vitro and in vivo studies, such as drug release kinetics, cytotoxicity assays, and pharmacodynamic and pharmacokinetic assessments to validate its enhanced efficacy and reduced toxicity. The clinical advantages of liposomal formulations are underscored by their ability to mitigate Doxorubicin’s cardiotoxic effects and improve therapeutic response in cancers like breast cancer, ovarian cancer, and Kaposi’s sarcoma.

Liposomal drug delivery, Doxorubicin Hydrochloride, chemotherapy, bioavailability, systemic toxicity, targeted delivery, formulation strategies, PEGylation, encapsulation efficiency, characterization techniques, pharmacokinetics, cardiotoxicity, cancer therapy, nanomedicine, controlled release, in vitro evaluation, in vivo studies.

"FORMULATION AND EVALUATION OF LIPOSOMAL DRUG DELIVERY SYSTEM FOR DOXORUBICIN HYDROCHLORIDE", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.12, Issue 8, page no.d330-d337, August-2025, Available :http://www.jetir.org/papers/JETIR2508338.pdf

"FORMULATION AND EVALUATION OF LIPOSOMAL DRUG DELIVERY SYSTEM FOR DOXORUBICIN HYDROCHLORIDE", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.12, Issue 8, page no. ppd330-d337, August-2025, Available at : http://www.jetir.org/papers/JETIR2508338.pdf